November 14, 2008 - A stent that entices artery-lining cells to coat it works as well, or better than, drug-eluting stents (DES) in keeping arteries open in coronary heart disease patients, according to two research studies presented this week at the American Heart Association's Scientific Sessions 2008 in New Orleans.

November 14, 2008 – Overall, in patients with a common form of non-STEMI there is not a significant difference in the combined endpoint of death, heart attack or stroke at six months whether their diagnostic angiogram is performed within 24 hours of the non-STEMI or days later, according to research released at AHA 2008 this week.

November 13, 2008 - Based on its recent analysis of the drug eluting-stents (DES) market, Frost & Sullivan today recognized Boston Scientific with the 2008 North American Frost & Sullivan Market Leadership Award, highlighting important milestones for Boston Scientific, including FDA approvals for the PROMUS Everolimus-Eluting Coronary Stent System, the TAXUS Express2, Atom Stent, and the company's second-generation TAXUS Liberte Stent.

November 13, 2008 - Medtronic Inc. said yesterday its enrollment in the 2,300-patient RESOLUTE All-Comers (R-AC) clinical study was completed in just six months, two months ahead of schedule.

The randomized trial compares the safety and efficacy of Medtronic's Endeavor Resolute drug-eluting stent (DES) with Abbott Laboratories' Xience DES.